Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma

Kang, YB; Sundaramoorthy, P; Gasparetto, C; Feinberg, D; Fan, SJ; Long, GY; Sellars, E; Garrett, A; Tuchman, SA; Reeves, BN; Li, ZG; Liu, B; Ogretmen, B; Maines, L; Ben-Yair, VK; Smith, C; Plasse, T

Kang, YB (通讯作者)，Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, 2400 Pratt St,Suite 5000,DUMC 396127710, Durham, NC 27708 USA.

ANNALS OF HEMATOLOGY, 2023; 102 (2): 369

Abstract

Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索